Endostatin
- Generic Name
- Endostatin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 187888-07-9
- Unique Ingredient Identifier
- 67RHC0R671
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
- Associated Conditions
- -
- Associated Therapies
- -
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01612286
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT01218594
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
Phase 2
- Conditions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT01192230
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2010-05-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 250
- Registration Number
- NCT01124253
- Locations
- 🇨🇳
The Lung Cancer Center of shanghai chest Hospital, Shanghai, China
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 1108
- Registration Number
- NCT00576914
- Locations
- 🇨🇳
The Lung Cancer Center of Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath